Small molecule · Acts on amyloid beta neuritic plaques · developed by Lantheus
Florbetaben F 18 is a radioactive diagnostic agent used with positron emission tomography (PET) to estimate amyloid beta neuritic plaque density in the brain. It is studied for imaging of amyloid pathology in Alzheimer's disease and in the heart in cardiac amyloidosis.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jul 24, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02681172 | Phase 4 | Alzheimer's Disease (AD) | Completed | LNTH |
| NCT06790394 | Phase 1 | Cardiac Amyloidosis | Completed | LNTH |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alzheimer's Disease (AD)Cardiac Amyloidosis
Updated Nov 15, 2026. Something wrong or missing? Report it on the LNTH page.
See LNTH's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LNTH catalysts and pipeline →